Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

← catalyst calendar

NCT05844228

Sponsored by Vir Biotechnology, Inc. (industry) · VIR — their whole pipeline →.

Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
28actual
Sites
3
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-06-01actualWhen the study began enrolling
Primary completion2025-03-01actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-04-21actualThe whole study's end, after follow-up
First posted2023-05-06actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2025-06-13actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Renal Impairment

Intervention

  • Drug: VIR-2218 — also filed as Elebsiran

Primary outcomes

what the primary-completion date above is the date OF
Maximum Observed Plasma Concentration (Cmax) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218
measured 5 days
Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration (AUClast) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218
measured 5 days
Area Under the Plasma Concentration-time Curve from Time Zero to Infinity (AUCinf) of VIR-2218 and its metabolite AS(N-1)3'VIR-2218
measured 5 days
Fraction excreted in urine in percentage for VIR-2218 and its metabolite AS(N-1)3'VIR-2218
measured 5 days
Amount excreted in urine for VIR-2218 and its metabolite AS(N-1)3'VIR-2218
measured 5 days
Renal clearance for VIR-2218 and its metabolite AS(N-1)3'VIR-2218
measured 5 days

Permalink · VIR's whole pipeline · Catalyst calendar · Every registered study · What changed